SLGL Earnings Date & History
Sol Gel Technologies Ltd (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:18 PM ET
Sol Gel Technologies Ltd
Pharmaceuticals
- Next earnings date
- Wednesday, November 18, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-2.67
- Revenue estimate
- $765,000
SLGL earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Thursday, May 28, 2026 | Q1 2026 | $-1.88 | $-1.31 | +30.2% | $108,000 |
| Thursday, March 19, 2026 | Q4 2025 | $0.40 | $-1.07 | -369.0% | $696,000 |
| Thursday, November 20, 2025 | Q3 2025 | $-2.13 | $-2.13 | +0.1% | $400,000 |
What the market is watching in SLGL's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next SLGL earnings date?
- Sol Gel Technologies Ltd is scheduled to report on Wednesday, November 18, 2026 (Time TBD). Dates can change until the company confirms them.
- Does SLGL report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for SLGL?
- Consensus EPS for the upcoming quarter is $-2.67, on revenue of $765,000.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
SLGL earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.